Mariana Lazo

Mariana Lazo

Auto-generated profile, based on publicly available information

Mariana Lazo

Department of Community Health and Prevention, Drexel Dornsife School of Public Health, Philadelphia, PA, USA; Urban Health Collaborative, Drexel Dornsife School of Public Health, Philadelphia, PA, USA; Division of General Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2013 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MLMariana Lazo
Mariana Lazo
RHRuben Hernaez
Ruben Hernaez
MEMark S. Eberhardt
Mark S. Eberhardt
SBSusanne Bonekamp
Susanne Bonekamp
IKIhab Kamel
Ihab Kamel
JCJeanne M. Clark
Jeanne M. Clark
Previous estimates of the prevalence of nonalcoholic fatty liver disease (NAFLD) in the US population relied on measures of liver enzymes, potentially underestimating the burden of this disease. We used ultrasonography data from 12,454 adults who participated in the Third National Health and Nutrition Examination Survey, conducted in the United States from 1988 to 1994. We defined NAFLD as the presence of hepatic steatosis on ultrasonography in the absence of elevated alcohol consumption. In the US population, the rates of prevalence of hepatic steatosis and NAFLD were 21.4% and 19.0%, respectively, corresponding to estimates of 32.5 (95% confidence interval: 29.9, 35.0) million adults with hepatic steatosis and 28.8 (95% confidence interval: 26.6, 31.2) million adults with NAFLD nationwide. After adjustment for age, income, education, body mass index (weight (kg)/height (m)2), and diabetes status, NAFLD was more common in Mexican Americans (24.1%) compared with non-Hispanic whites (17.8%) and non-Hispanic blacks (13.5%) (P = 0.001) and in men (20.2%) compared with women (15.8%) (P < 0.001). Hepatic steatosis and NAFLD were also independently associated with diabetes, with insulin resistance among people without diabetes, with dyslipidemia, and with obesity. Our results extend previous national estimates of the prevalence of NAFLD in the US population and highlight the burden of this disease. Men, Mexican Americans, and people with diabetes and obesity are the most affected groups.

27 October 2008 in Seminars in Liver Disease
Verified
Journal Article
Closed access
PDF file
MLMariana Lazo
Mariana Lazo
JCJeanne M. Clark
Jeanne M. Clark
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease in the United States and worldwide. With obesity being an important risk factor universally, NAFLD is now receiving greater attention and is regarded as a public health issue. In addition, as a result of an aging population and the improving control of other major causes of chronic liver disease, such as hepatitis C and hepatitis B, the burden of NAFLD is expected to increase in years to come. Prevalence estimates of this disease vary widely across populations because of differences in methods for diagnosis and/or definition. New strategies for the prevention, diagnosis, and management will be required to alter the course of this disease.

18 November 2011 in BMJ
Verified
Journal Article
Open access
PDF file
MLMariana Lazo
Mariana Lazo
RHRuben Hernaez
Ruben Hernaez
SBSusanne Bonekamp
Susanne Bonekamp
IKIhab R Kamel
Ihab R Kamel
FBFrederick L Brancati
Frederick L Brancati
JCJeanne M Clark
Jeanne M Clark
Objective To evaluate the association between non-alcoholic fatty liver disease and all cause and cause specific mortality in a representative sample of the US general population.Design Prospective cohort study.Setting US Third National Health and Nutrition Examination Survey (NHANES III: 1988-94) with follow-up of mortality to 2006.Participants 11 371 adults aged 20-74 participating in the Third National Health and Nutrition Examination Survey, with assessment of hepatic steatosis.Main outcome measure Mortality from all causes, cardiovascular disease, cancer, and liver disease (up to 18 years of follow-up).Results The prevalence of non-alcoholic fatty liver disease with and without increased levels of liver enzymes in the population was 3.1% and 16.4%, respectively. Compared with participants without steatosis, those with non-alcoholic fatty liver disease but normal liver enzyme levels had multivariate adjusted hazard ratios for deaths from all causes of 0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver disease of 0.64 (0.12 to 3.59). Compared with participants without steatosis, those with non-alcoholic fatty liver disease and increased liver enzyme levels had adjusted hazard ratios for deaths from all causes of 0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20), from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15 to 8.93).Conclusions Non-alcoholic fatty liver disease was not associated with an increased risk of death from all causes, cardiovascular disease, cancer, or liver disease.

27 July 2010 in Diabetes Care
Verified
Journal Article
Open access
MLMariana Lazo
Mariana Lazo
SSSteven F. Solga
Steven F. Solga
AHAlena Horska
Alena Horska
SBSusanne Bonekamp
Susanne Bonekamp
ADAnna Mae Diehl
Anna Mae Diehl
FGfor the Fatty Liver Subgroup of the Look AHEAD Research Group
for the Fatty Liver Subgroup of the Look AHEAD Research Group
OBJECTIVE: Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS: Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS: Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (−8.5 vs. −0.05%; P < 0.01) than those assigned to DSE and had a greater decline in steatosis (−50.8 vs. −22.8%; P = 0.04) and in A1C (−0.7 vs. −0.2%; P = 0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P < 0.05). CONCLUSIONS: A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.

15 November 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MLMariana Lazo
Mariana Lazo
SGStephen J. Gange
Stephen J. Gange
TWTracey E. Wilson
Tracey E. Wilson
KAKathryn Anastos
Kathryn Anastos
DODavid G. Ostrow
David G. Ostrow
LJLisa P. Jacobson
Lisa P. Jacobson
Background. Adherence to therapy is a dynamic behavior. However, few studies have identified factors associated with changes in adherence to highly a

9 February 2016 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JPJosée Poirier
Josée Poirier
WBWendy L Bennett
Wendy L Bennett
GJGerald Jerome
Gerald Jerome
NSNina G Shah
Nina G Shah
MLMariana Lazo
Mariana Lazo
NCNathan K Cobb
Nathan K Cobb
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet